Last reviewed · How we verify

PGL4001 (ulipristal) and iron

PregLem SA · Phase 3 active Small molecule

PGL4001 (ulipristal) and iron is a Selective progesterone receptor modulator with iron supplementation Small molecule drug developed by PregLem SA. It is currently in Phase 3 development for Uterine fibroids (leiomyomas) with heavy menstrual bleeding, Iron deficiency anemia secondary to heavy menstrual bleeding. Also known as: Ulipristal acetate.

Ulipristal is a selective progesterone receptor modulator that suppresses ovulation and alters the endometrium, while iron supplementation addresses iron deficiency anemia.

Ulipristal is a selective progesterone receptor modulator that suppresses ovulation and alters the endometrium, while iron supplementation addresses iron deficiency anemia. Used for Uterine fibroids (leiomyomas) with heavy menstrual bleeding, Iron deficiency anemia secondary to heavy menstrual bleeding.

At a glance

Generic namePGL4001 (ulipristal) and iron
Also known asUlipristal acetate
SponsorPregLem SA
Drug classSelective progesterone receptor modulator with iron supplementation
TargetProgesterone receptor (PR); iron supplementation (non-receptor target)
ModalitySmall molecule
Therapeutic areaGynecology / Women's Health
PhasePhase 3

Mechanism of action

Ulipristal acetate acts as a selective progesterone receptor agonist/antagonist, disrupting the luteinizing hormone surge necessary for ovulation and modifying endometrial proliferation. The iron component provides supplemental iron to treat or prevent iron deficiency anemia, which may occur secondary to heavy menstrual bleeding. This combination targets both the hormonal and hematologic aspects of conditions like uterine fibroids.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PGL4001 (ulipristal) and iron

What is PGL4001 (ulipristal) and iron?

PGL4001 (ulipristal) and iron is a Selective progesterone receptor modulator with iron supplementation drug developed by PregLem SA, indicated for Uterine fibroids (leiomyomas) with heavy menstrual bleeding, Iron deficiency anemia secondary to heavy menstrual bleeding.

How does PGL4001 (ulipristal) and iron work?

Ulipristal is a selective progesterone receptor modulator that suppresses ovulation and alters the endometrium, while iron supplementation addresses iron deficiency anemia.

What is PGL4001 (ulipristal) and iron used for?

PGL4001 (ulipristal) and iron is indicated for Uterine fibroids (leiomyomas) with heavy menstrual bleeding, Iron deficiency anemia secondary to heavy menstrual bleeding.

Who makes PGL4001 (ulipristal) and iron?

PGL4001 (ulipristal) and iron is developed by PregLem SA (see full PregLem SA pipeline at /company/preglem-sa).

Is PGL4001 (ulipristal) and iron also known as anything else?

PGL4001 (ulipristal) and iron is also known as Ulipristal acetate.

What drug class is PGL4001 (ulipristal) and iron in?

PGL4001 (ulipristal) and iron belongs to the Selective progesterone receptor modulator with iron supplementation class. See all Selective progesterone receptor modulator with iron supplementation drugs at /class/selective-progesterone-receptor-modulator-with-iron-supplementation.

What development phase is PGL4001 (ulipristal) and iron in?

PGL4001 (ulipristal) and iron is in Phase 3.

What are the side effects of PGL4001 (ulipristal) and iron?

Common side effects of PGL4001 (ulipristal) and iron include Headache, Abdominal pain, Nausea, Amenorrhea or oligomenorrhea, Hot flushes.

What does PGL4001 (ulipristal) and iron target?

PGL4001 (ulipristal) and iron targets Progesterone receptor (PR); iron supplementation (non-receptor target) and is a Selective progesterone receptor modulator with iron supplementation.

Related